Factors Associated with Response, Neurotoxicity, and Survival in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell (CAR-T) therapy

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-09-01 DOI:10.1016/S2152-2650(25)03486-X

Jesus Salas, Tuan Phan, Yevgeniya Gokun, Naresh Bumma, Elvira Umyarova, Srinivas Devarakonda, Abdullah Khan, Ashley Rosko, Sarah Wall, Marcos De Lima, Sumithira Vasu, Tirisham Gyang, Don Benson, Francesca Cottini

引用次数: 0

查看原文本刊更多论文

嵌合抗原受体t细胞（CAR-T）治疗多发性骨髓瘤患者的反应、神经毒性和生存相关因素

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.